BC Platforms is a Finnish research-intensive SME whose core competencies are in building powerful software and providing researchers with the technology that enables them to drive advances in understanding complex genetic data. We are a trusted partner or a subcontractor in various EU FP7 HEALTH projects, doing our share in promoting knowledge sharing and working across borders. Our role in these projects is to a deliver collaborative life science research database, customized for the needs of each project.

In addition to setting up the data integration and sharing platform, we offer user training and ongoing support throughout the project. The software platform can also be connected to a calculation resource enabling highly efficient data analysis. All project background and foreground data are federated into the central database and shared with various investigators on a need-to-know basis.

Since all of the data analysis can be performed inside the system framework, there is no need to export and distribute copies of the data, thus enabling a high level of data security. A comprehensive database audit trail and logfile functionality, together with legal agreements, ensures safe data-sharing and provides for an efficient research collaboration environment.

We are interested in new partnership and subcontracting possibilities in the fields of bioinformatics, genetic epidemiology & statistical genetics, biobanking and personalized/precision medicine.


SUMMIT (Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools) is a pan-European research consortium funded by the Innovative Medicines Initiative (IMI). The IMI is a public/private partnership between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SUMMIT brings together the scientific expertise and clinical resources from 19 leading universities and research institutes, four pharmaceutical companies and one small or medium sized enterprise (BC Platforms).

SUMMIT plans to systematically identify genetic risk factors for chronic diabetic complications. A collection of patient samples from a variety of cohorts will be analyzed by high-throughput techniques (e.g. genotyping by DNA microarrays) and both patient samples and newly discovered genotypes will be applied for biomarker discovery. The goal is to deliver a set of biomarkers able to better predict disease progression and drug effects and thereby to shorten the time required for clinical trials and drug approval. In accordance with the IMI research agenda, SUMMIT will help to accelerate the process of bringing new medicines to patients by increasing the efficiency and reduce the cost of medicine development.


Over 50 million people across the world suffer from epilepsy, making it the most common serious neurological disorder for which there is no cure. The causes for epilepsy are insufficiently understood with currently available treatments being sub-optimal and with a significant proportion of patients not responding. Recent discoveries have identified a new type of molecule in cells called microRNA which may be critical to controlling the changes in brain chemistry that accompany the development and course of epilepsy. The EpimiRNA Consortium represents a major interdisciplinary effort between epilepsy researchers, geneticists, clinicians, experts in advanced molecular sciences and research-active companies working together to understand molecular mechanisms, diagnostics and developing novel microRNA-based therapeutics to prevent the development of epilepsy, the occurrence of seizures or reverse epilepsy once established.

Coordinated by Professor David Henshall from the Royal College of Surgeons in Ireland, the Consortium is made up of partners at Philipps University Marburg, University Medical Center Utrecht, University College London, Duke University, Aarhus University, and more. The project is funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under Grant Agreement n°602130.


Complex disorders such as obesity, type 2 diabetes (T2D) and metabolic syndrome (MetS) make a major contribution to overall health expenses in the 21st century. In Europe there are 41 million immigrants, equivalent to 8.6% of the European Community (EC) population. As a function of admixture and cultural habits (aculturation), immigrant genetic predisposition enters into collision with the westernized way of life resulting in protective or pathogenic effects. By combining genetic and anthropological data of 5 immigrant groups in Mediterranean Europe, the MEDIGENE (Genetic and environmental factors of insulin resistance syndrome and its long-term complications in immigrant Mediterranean populations) will provide epidemiological models that contribute to better diagnosis and treatment of MetS.


The main goal of the DENFREE (Dengue research Framework for Resisting Epidemics in Europe) project is to find key factors determining dengue transmission and dynamics in order to develop new tools and strategies for controlling dengue transmission. Project will generate predictive models about the epidemics, and also aim to develop an easy-to-use point of care diagnostic tool that is sensitive to detect virus in both human and mosquito samples. The research leading to these results has received funding from the European Commission Seventh Framework Programme [FP7/2007-2013] for the DENFREE project under Grant Agreement n°282 378.


The CELL-O-MATIC (High Throughput Systematic Single-cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysing, Selecting and Preparing Sequence-ready DNA) project will develop chip-based systems that process DNA from individual cells, ready for next generation high-throughput sequencing. The project will also develop methods that enable up to whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. A modular prototype comprising a chip, fluid and thermal control, sonification and optical detection will be developed.


MIMOmics (Methods for Integrated analysis of multiple Omics datasets) develops statistical methods for the integrated analysis of metabolomics, proteomics, glycomics and genomic datasets in large studies. The state-of-the-art methodology does not match by far the complexity of the biological problem. Complex data are being analysed in a rather simple way which misses the opportunity to uncover combinations of predictive profiles among the omics data.
The objectives of MIMOmics are: 1) to develop a statistical framework of methods for all analysis steps needed for identifying and interpreting omics-based biomarkers and 2) to integrate data derived from multiple omics platforms across several study designs and populations.


In the GEN2PHEN project 20 academic and SME partners from all over Europe worked together to unify human and model organism genetic variation databases towards increasingly holistic views into Genotype-To-Phenotype (G2P) data, and to link this system into other biomedical knowledge sources via genome browser functionality. The project analysed the G2P field to determine emerging needs and practices and developed standards, generic database components, services and integration infrastructures for the G2P database domain. It created search modalities and data presentation solutions for G2P knowledge in the aim to facilitate the process of populating G2P databases.


Dogs tend to suffer from the same range of diseases as humans, but the genetic complexity of diseases within a breed is reduced as a consequence of inbreeding. Due to a significant level of linkage disequilibrium in dog breeds (i.e., non-random allelic association), the number of SNP markers needed to perform whole genome scans at least ten-fold lower than that needed to perform similar studies for human disease-gene association. The LUPA initiative is a European research project gathering experts in genomics to take advantage of this extraordinary genetic model. Veterinary clinics from 12 European countries are collecting DNA samples from large cohorts of dogs suffering from a range of well-defined diseases of relevance to human health. This innovative approach to providing insights into the pathogenesis of common human diseases, by using the dog model, will accelerate identification of important human disease genes – the project’s primary goal.


The aim of the DIABIMMUNE project is to assess the role of the hygiene hypothesis in the development of immune-mediated diseases. Type 1 diabetes (juvenile onset diabetes) is a primary target of this study. The overall goal of the study is to define the mechanisms behind the potential protective effect conferred by microbial agents. The study design comprises two cohorts: a birth cohort and a cohort comprising young children. The objective is to study 2,000 children between 3 to 5 years old, and to observe 320 newborn infants with an increased genetic risk for autoimmune disease, from birth up to the age of 3 years. The estimated number of study subjects will altogether be approximately 7,000 with Finland, Russian Karelia and Estonia each contributing around 2,320 subjects. The project is funded by the European Commission (FP7).

Want to know more? Let’s talk

Get in touch